Begin main content

New at CADTH - January 2019

Last updated: January 9, 2019
Product Line: New at CADTH
Result type: Report

News and Events

Save the date. The 2019 CADTH Symposium is being held in Edmonton, Alberta, from April 14 to 16, 2019. Applications for the CADTH Recognition Awards are open until January 14, 2019.

Drug Reimbursement Recommendations

CADTH recently issued the following CADTH Canadian Drug Expert Committee (CDEC) drug reimbursement recommendations:

CADTH recently issued the following pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC) drug reimbursement recommendations:

  • pertuzumab-trastuzumab (Perjeta-Herceptin) combo pack for the adjuvant treatment of HER2-positive early breast cancer patients at high risk of recurrence
  • nivolumab (Opdivo) for the treatment of adult patients with advanced (not amenable to curative therapy or local therapeutic measures) or metastatic hepatocellular carcinoma who are intolerant to or have progressed on sorafenib therapy.

CADTH Reports

CADTH recently completed the following reports:

Rapid Response Reports — Drug

Rapid Response Reports — Medical Devices and Systems


Tell Us What You Think

We love hearing how our products and services are influencing health care policies, clinical practices, and patient outcomes. If you have a success story to share, please get in touch with your CADTH Liaison Officer.

CADTH E-Alerts: Subscribe to receive the latest CADTH news, reports, feedback opportunities, and events.